Faron Pharmaceuticals Oy (GB:FARN)

LSE:FARN

FARN

Faron Pharmaceuticals Oy

RESEARCH TOOLSreports

Faron Pharmaceuticals Oy (FARN) Price & Analysis

Compare

70 Followers

FARN Stock Chart & Stats

43.50 p

-2.73 p(-1.37%)

At close: Jan 09 4:00 PM EST

43.50 p

-2.73 p(-1.37%)

Day’s Range― - ―

52-Week Range41.00 p - 259.05 p

Previous CloseN/A

Volume750.00

Average Volume (3M)46.62K

Market Cap

£85.24M

Enterprise Value270.38M

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.86

Next Earnings

Sep 01, 2026

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding199,630,780

10 Day Avg. Volume70,409

30 Day Avg. Volume46,616

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£1,000.00

Price Target Upside2198.85% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Capital EfficiencyUse of complete response as the primary approval measure lowers patient enrollment needs and improves capital efficiency for the registrational pathway.

Clinical Efficacy SignalEarly-stage trial responses, including in a hard-to-treat genetic subgroup, suggest potential for meaningful survival improvement and expansion into additional indications.

Financial StrengthStrengthened balance sheet enables funding of pivotal MDS development and multiple solid-tumor trials without immediate reliance on a commercial partner.

Bears Say

Clinical Precedent RiskPublished late-stage failures in similar MDS programs highlight the high technical risk inherent to MDS trials and could weaken confidence in new pivotal studies.

Investor SentimentLate-stage setbacks in the field can increase market caution and amplify share price volatility ahead of pivotal readouts.

Partnering HesitancyHistorical trial failures may make potential pharmaceutical partners more cautious, complicating collaboration prospects and access to external resources.

Faron Pharmaceuticals Oy News

Faron bolsters late-stage push with new CTO for lead cancer immunotherapy

The latest update is out from Faron Pharmaceuticals Oy ( ($GB:FARN) ). Faron Pharmaceuticals has appointed Heikki Jouttijärvi...

4d ago

Buy Rating Reiterated on Faron: De-Risked Bexmarilimab Strategy in High-Risk MDS and Upside from Solid Tumor Expansion

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Faron Pharmaceuticals Oy,...

11d ago

Faron CEO Boosts Stake in Rights Issue, Underscoring Confidence in Cancer Immunotherapy Pipeline

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has provided an update. Faron Pharmaceuticals announced that CEO Juho Jalkanen has...

11d ago

Faron Senior Advisor Boosts Stake as Cancer Immunotherapy Trials Advance

The latest update is out from Faron Pharmaceuticals Oy ( ($GB:FARN) ). Faron Pharmaceuticals reported that senior advisor...

11d ago

Faron General Counsel Ups Stake in Rights Issue, Signaling Confidence in Immunotherapy Pipeline

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has provided an announcement. Faron Pharmaceuticals reported that Pacta sunt servanda Oy,...

11d ago

Faron wins regulator nod for €40m rights issue to fund immunotherapy pipeline

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has issued an update. Faron Pharmaceuticals has received approval from the Finnish...

19d ago

Faron launches fully covered EUR 40m rights issue to fund cancer drug trials and extend cash runway

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has shared an announcement. Faron Pharmaceuticals has launched a fully covered rights...

20d ago

Faron Reschedules 2026 AGM While Keeping Half-Year Report Date Unchanged

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has issued an announcement. Faron Pharmaceuticals has adjusted its 2026 corporate calendar,...

21d ago

Faron Pharmaceuticals Corrects 2025 Annual Report to Add Missing Auditor’s Report

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has shared an announcement. Faron Pharmaceuticals Ltd has issued a correction to...

26d ago

Faron Pharmaceuticals Publishes 2025 Annual Report Detailing Progress in Cancer Immunotherapies

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has issued an update. Faron Pharmaceuticals has published its Annual Report for...

26d ago

FARN FAQ

What was Faron Pharmaceuticals Oy’s price range in the past 12 months?

Faron Pharmaceuticals Oy lowest share price was 41.00 p and its highest was 259.05 p in the past 12 months.

What is Faron Pharmaceuticals Oy’s market cap?

Faron Pharmaceuticals Oy’s market cap is £85.24M.

When is Faron Pharmaceuticals Oy’s upcoming earnings report date?

Faron Pharmaceuticals Oy’s upcoming earnings report date is Sep 01, 2026 which is in 155 days.

How were Faron Pharmaceuticals Oy’s earnings last quarter?

Faron Pharmaceuticals Oy released its earnings results on Mar 04, 2026. The company reported -0.059 p earnings per share for the quarter, beating the consensus estimate of -0.087 p by 0.028 p.

Is Faron Pharmaceuticals Oy overvalued?

According to Wall Street analysts Faron Pharmaceuticals Oy’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Faron Pharmaceuticals Oy pay dividends?

Faron Pharmaceuticals Oy does not currently pay dividends.

What is Faron Pharmaceuticals Oy’s EPS estimate?

Faron Pharmaceuticals Oy’s EPS estimate is -0.04.

How many shares outstanding does Faron Pharmaceuticals Oy have?

Faron Pharmaceuticals Oy has 199,630,780 shares outstanding.

What happened to Faron Pharmaceuticals Oy’s price movement after its last earnings report?

Faron Pharmaceuticals Oy reported an EPS of -0.059 p in its last earnings report, beating expectations of -0.087 p. Following the earnings report the stock price went up 13.725%.

Which hedge fund is a major shareholder of Faron Pharmaceuticals Oy?

Currently, no hedge funds are holding shares in GB:FARN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Faron Pharmaceuticals Oy (FARN) Earnings & Revenues

Historic Earnings Reports

FARN Stock 12 Month Forecast

Average Price Target

1,000.00 p

▲(2198.85% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"50":"50 p","1001":"1,001 p","287.75":"287.8 p","525.5":"525.5 p","763.25":"763.3 p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">1.00K </span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">1.00K </span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">1.00K </span>\n  </div></div>","useHTML":true}}],"tickPositions":[50,287.75,525.5,763.25,1001],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,51.331,124.30553846153846,197.28007692307693,270.25461538461536,343.22915384615385,416.20369230769234,489.17823076923077,562.1527692307692,635.1273076923077,708.1018461538462,781.0763846153847,854.050923076923,927.0254615384615,{"y":1000,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,51.331,124.30553846153846,197.28007692307693,270.25461538461536,343.22915384615385,416.20369230769234,489.17823076923077,562.1527692307692,635.1273076923077,708.1018461538462,781.0763846153847,854.050923076923,927.0254615384615,{"y":1000,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,51.331,124.30553846153846,197.28007692307693,270.25461538461536,343.22915384615385,416.20369230769234,489.17823076923077,562.1527692307692,635.1273076923077,708.1018461538462,781.0763846153847,854.050923076923,927.0254615384615,{"y":1000,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":165.506,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":163.108,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":200.526,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":184.695,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":242.263,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":194.29,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.695,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":196.689,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.702,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":194.29,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.297,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":163.108,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.331,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >